Protection of Mice Against Encephalomyocarditis Virus Infection by Chemically Modified Transfer RNAs
(Accepted 24 March I977) SUMMARY Periodate or nitrous acid treatment greatly decreases the ability of unfractionated Escheriehia coli transfer RNA (tRNA) to be aminoacylated by tRNAsynthetases but these treatments do not affect their antiviral activity against encephalomyocarditis virus infection of mice. Bisulphite treatment of E. coli tRNA reduces its ability to be aminoacylated by 2~% and has no effect on antiviral activity. Bromine water treatment of tRNA under conditions causing extensive base modifications eliminates aminoacylation and the antiviral activity of E. coli tRNA. Periodate treatment of yeast tRNA does not affect its antiviral activity and nitrous acid treatment increases its antiviral activity to that of E. coli tRNA. The ability to be aminoacylated does not therefore appear to be essential for antiviral activity of tRNA but extensive modification (bromine water treatment) does destroy antiviral activity.
Unfractionated preparations of transfer RNA (tRNA) particularly from bacteria, have been shown to protect mice against encephalomyocarditis (EMC) virus infection (Stebbing et al. ~976b ). The 37S virus RNA from purified EMC virus contains a tRNA-like structure but is not at the 3'-terminus and cannot therefore be aminoacylated while still part of the intact virus RNA molecule (Lindley & Stebbing, x976) . There is no evidence that the antiviral effect of tRNA against EMC virus infection is mediated by interferon (Stebbing et al. ~976b) . The antiviral effect of tRNA could be mediated by mimicking the tRNA-like structure in the virus RNA (see Stebbing et al. I976b) or by directly affecting the intracellular tRNA pools that donate amino acids during protein synthesis. In the former case, blockage of amino acid donor activity of tRNA preparations should not abolish antiviral activity, while in the latter case blocked, non-aminoacylatable tRNAs would be expected to behave differently from normal, aminoacylatable tRNAs. We have therefore examined the effect of treating tRNA preparations with periodate or nitrous acid, which virtually eliminate aminoacylation of tRNA. We also examined the effect of two other chemical treatments: we chose bisulphite conversion of cytidylate residues to uridylate and bromine water treatment under conditions causing extensive base modifications.
Female mice (BK:W, from Bantin & Kingman Ltd, Hull, U.K.) were infected with EMC virus which was grown and stored as previously described (Stebbing, Grantham & Carey, I976a ) . Virus dilutions and tRNA preparations were all made up in 0"89% (w/v) NaC1, to mM-Hepes, pH 7"5 (HBS) and injected intraperitoneally or intravenously into one of the lateral tail veins of mice in a volume of o.I ml, as described previously. E. coli tRNA was obtained from British Drug Houses Ltd, Poole, Dorset and yeast tRNA (type I) from Sigma Chemical Co. Ltd. No deaths occurred between ~8 and 3o days post-infection after which time the experiments were terminated. Mice surviving to ~8 days are therefore termed survivors. Significant differences in the survival times of different groups of mice were tested for by calculating X 2 values by the logrank method described by Peto & Pike :23 vlR 36 352 Short communications 0973) on the survival data up to I8 days post-infection. This is a non-parametric analytical method that takes account of surviving mice as well as delays in death. The significance levels of X 2 values are indicated by asterisks as follows: ***, P < o-ooi; **, P < o-or; *, P < o.o5. No asterisk indicates P > o.o 5 and is taken as non-significant. We wished to study the effects of our tRNA treatments against lethal doses of virus and virus titrations are therefore given in terms of LD10o. These values were estimated from determinations of LDs0 using an empirical conversion of ~2 × LDso= LD100. Up to I5% of mice in infected control groups of mice given I × LD100 survived infection.
Periodate oxidation was carried out on tRNA at 5 mg/ml in o'o5 M-sodium acetate, pH 5, as described by Dulbecco & Smith (I96o) . A Ioo-fold molar excess of sodium metaperiodate was added and after I h at 2o °C in the dark 2 vol. cold ethanol was added to precipitate the oxidized tRNA. This precipitate was dissolved in o'o5 M-sodium acetate, pH 5, re-precipitated and then dried. Nitrous acid deamination was carried out on tRNA at 5 mg/ml in o'25 M-sodium acetate (pH 4"3) as described by Carbon (I970. The reaction was allowed to continue at room temperature for 4"5 h and halted by addition of 2 vol. ice-cold ethanol. The precipitate was dissolved in o-25 M-sodium acetate (pH 7-2) and re-precipitated with ethanol before desiccation. Bisulphite conversion of cytidylate residues in singlestranded regions of tRNA molecules was carried out by the method of Kucan et al. (I 97 I) : 2o mg tRNA in 27 ml water plus 8.2o8 g sodium metabisulphite and 55 mg magnesium chloride were incubated at pH 5"8 for 25 h at 25 °C and the tRNA then precipitated by addition of 2 vol. of ice-cold ethanol. Bromine water treatment of tRNA was carried out by a modification of the methods of and Eaton & Hutchinson (I 973) . Bromine water was added to tRNA dissolved in water at a concentration of 25 mg/ml at o °C and the pH held at 7.0 by means of a pH-stat. When the solution just turned yellow, cyclohexene was added until the solution was colourless. This solution was adjusted to pH 9"5 at 37 °C and after 4 h the product was pumped through two biofibre 5 ° beakers (Biorad Laboratories). The salt-free polymer was then lyophilized. These conditions are more vigorous than those employed by Means & Fraenkel-Conrat 0970 and when carried out on polyribocytidylic acid the product contained about 40% bromocytidylate residues with the remaining residues reduced further to hydroxycytidylate residues (Stebbing, Lindley & Eaton, I977) . Less vigorous bromine water treatment is also known to cause extensive modifications to tRNA (Zamecnik & Yu, I970. The base composition of our bromine water treated tRNA was not analysed but we presume, from the observation that the method completely changes polycytidylic acid and the observations of Brammer (1963) and Zamecnik & Yu 0970, that the majority of the pyrimidine residues were modified and that while some guanylate residues may also have reacted, the adenylate residues were probably unaltered.
All the modified tRNA preparations were examined on 5"o% polyacrylamide gels by the method of Loening (I 969) and their ability to accept 3H-labelled amino acids in the presence of tRNA synthetases was also checked using the procedure described previously (Lindley & Stebbing, I976) . In all cases the modified tRNAs showed essentially the same profile of migration in gels as untreated tRNA with over 94% of the u.v. absorbing material migrating in the 4S position. The periodate and bromine water treatments completely abolished aminoacylation activity while the nitrous acid and bisulphite treatments caused 89% and 2o~o inhibition of aminoacylation, respectively.
Administration of E. coli tRNA 6 h before infection protects about 75% of mice against infection with a virus dose of approx. I × LD100 (see Fig. I shown in Fig. I but the number of surviving mice in these groups was I7, 15 and I6 respectively and logrank comparisons with the group treated with unmodified tRNA showed no significant differences. Doses of these modified E. coli tRNAs between lOO/zg/mouse and 2ooo/zg/mouse showed no significant differences in antiviral activity compared with the unmodified tRNA when administered 6 h before infection with three different virus doses. In contrast, administration of 40o/zg/mouse of bromine water treated E. coli tRNA caused no protection (see Fig. I ) and other results showed no significant protection with this material even at a dose of 2000 #g/mouse.
Although E. coli tRNA is also effective intravenously against intraperitoneal infections with EMC virus (Stebbing et al. I976b) , it seemed possible that the modified tRNAs could behave differently and merely exert local effects in the peritoneal cavity. We therefore compared the antiviral activity of the four modified forms of E. coli tRNA with the unmodified tRNA when all the materials were administered intravenously. The results were essentially the same as those obtained for the materials administered intraperitoneally.
Of the limited number of eukaryotic tRNA preparations previously examined only yeast tRNA type I from Sigma showed antiviral activity against EMC virus infection of mice (Stebbing et al. I976b) . On the basis that eukaryotic tRNA preparations are generally less antiviral than bacterial tRNAs because the eukaryotic tRNAs can be more extensively utilized for protein synthesis, we examined the antiviral activity of chemically modified eukaryotic tRNA preparations. From dose response data the antiviral activity of yeast ,tRNA (Sigma, type I) was found to be less active on a weight basis than bacterial tRNA preparations (our unpublished results). The data in Fig. I show that yeast tRNA (Sigma, type I) protects mice against EMC virus infection (I x LD10o) and that after nitrous acid treatment the antiviral activity of this tRNA is increased to that of bacterial tRNA. The protective effects of the untreated and treated yeast tRNAs were significant (X 2 values = Io. 12" * and 22-oi ** * respectively) and the modified tRNA was significantly better than the untreated tRNA (X 2 = 4"58*). Periodate treated yeast tRNA from the same source caused no change in the antiviral activity of the tRNA.
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